Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan

Int J Infect Dis. 2020 Aug:97:135-142. doi: 10.1016/j.ijid.2020.05.082. Epub 2020 May 29.

Abstract

Objectives: To assess the potential epidemiological impact and cost-effectiveness of shorter antibiotic regimens in high tuberculosis (TB) burden regions of Taiwan.

Methods: This study combined the TB population dynamic model and cost-effectiveness analysis with local data to simulate the disease burdens, effectiveness and costs of hypothetical 4-month, 2-month and 7-day regimens compared with the standard regimen.

Results: The main outcomes were the potential of shorter regimens for averted incidence, mortality and disability-adjusted life years, incremental cost-effectiveness ratio and net monetary benefit. Shorter regimens would lower incidence rates and mortality cases in a high TB burden region by an average of 19-33% and 27-41%, respectively, with the potential for cost-effectiveness or cost-saving. The 2-month and 7-day regimens would be more cost-effective than the 4-month regimen. The threshold daily drug prices for achieving cost-effectiveness and cost-saving for 4-month, 2-month and 7-day regimens were $US1, $US2 and $US70, respectively. Such cost-effectiveness would remain, even if the willingness-to-pay threshold was less than one gross domestic product per capita.

Conclusions: The findings support the inclusion of shorter regimens in global guidelines and regional-scale TB control strategies, which would improve disease control, particularly in settings with high rates of incidence and poor treatment outcomes.

Keywords: Antibiotic treatment; Economic evaluation; Population dynamic model; Shorter regimens; Tuberculosis.

MeSH terms

  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / therapeutic use*
  • Cost of Illness
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Humans
  • Quality-Adjusted Life Years
  • Taiwan
  • Time Factors
  • Treatment Outcome
  • Tuberculosis / drug therapy*
  • Tuberculosis / epidemiology

Substances

  • Antitubercular Agents